Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme.The clinical administration follows the Company's ...

Core Insights - Viatris reported strong financial results for Q4 and full year 2025, with total revenues of $3.7 billion for Q4 and $14.3 billion for the full year, meeting or exceeding financial guidance across all key metrics [1][2][3] - The company completed an enterprise-wide strategic review, expecting to deliver $650 million in total cost savings while reinvesting up to $250 million over the next three years [1][3] - Viatris anticipates regulatory decisions for six product candidates in 2026 and multiple important pipeline milestones, positioning itself for sustainable growth [1][3] Financial Performance - Q4 2025 total revenues increased by 5% compared to Q4 2024, while full year revenues decreased by 3% compared to 2024 [2][3] - U.S. GAAP net loss for Q4 2025 was $340.1 million, a 34% improvement from a loss of $516.5 million in Q4 2024 [2][3] - Adjusted net earnings for Q4 2025 were $658.7 million, with adjusted EPS of $0.57, reflecting a 6% increase from Q4 2024 [2][3] Strategic Initiatives - The company initiated restructuring activities as part of its strategic review, expecting a global workforce reduction of up to 10% [3][6] - Total pre-tax charges related to restructuring are estimated between $700 million and $850 million, with anticipated savings of $600 million to $700 million once fully implemented [3][6] - Viatris plans to provide a balanced capital allocation approach for 2026, returning over $1 billion to shareholders in 2025 [1][3] Product Pipeline and Regulatory Updates - The company generated approximately $78 million in new product revenues in Q4 2025, with expectations of $450 million to $550 million in new product revenues for 2026 [2][3] - Viatris has several regulatory submissions under review, including a J-NDA for pitolisant in Japan and an NDA for a low-dose estrogen weekly patch in the U.S. [2][6] - The FDA has assigned a PDUFA goal date of July 30, 2026, for the low-dose estrogen patch and October 17, 2026, for MR-141 [6] Market Performance - Generics net sales were impacted by competition in North America and government price regulations in Japan, while brands net sales showed strength in Greater China and Emerging Markets [2][3] - The company expects continued operational growth driven by its base business and net cost savings in 2026 [1][3]

Core Viewpoint - Viatris Inc. has announced a 2026 dividend policy of $0.48 per share and a quarterly dividend of $0.12, marking the sixth consecutive year of dividend payments [1] Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name drugs, providing access to high-quality medicines for approximately 1 billion patients annually [1] - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India [1] Dividend Announcement - The Board of Directors approved a dividend policy of $0.48 per share for 2026 and declared a quarterly dividend of $0.12 per share [1] - The dividend is scheduled to be paid on March 18, 2026, to shareholders of record as of March 9, 2026 [1]

Core Insights - Eli Lilly released new data from a head-to-head trial comparing its experimental weight-loss pill orforglipron with Novo Nordisk's oral semaglutide in diabetes patients, highlighting the competitive landscape in the weight-loss medication market [1] Group 1: Trial Results - The trial demonstrated that orforglipron led to a greater percentage of weight loss compared to semaglutide, with patients on orforglipron losing an average of 15% of their body weight over a 16-week period [1] - Eli Lilly's orforglipron showed a favorable safety profile, with fewer gastrointestinal side effects reported compared to semaglutide [1] Group 2: Market Implications - The results position Eli Lilly to potentially capture a significant share of the growing weight-loss medication market, which is increasingly competitive with the presence of established players like Novo Nordisk [1] - Analysts suggest that the positive trial outcomes could enhance Eli Lilly's market valuation and investor interest in its pipeline of weight-loss treatments [1]

In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026 1,2 For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) toda ...

Across the pond, Salesforce shares fell in pre-market trading after its earnings , as its efforts to say "everything will be fine" fell on deaf ears as investors worry that AI might destroy prospects for business software providers.For LSEG it's AI assurances are being listened to more than others.“Kitchen seller Howden Joinery also continued its run of quietly getting on with the job and then reminding the market it can still take a step forward in a difficult market."The blue-chip UK index has is being "p ...

Management acknowledged challenges for the Injectables business in 2025 and 2026. Deputy CEO North America and Europe Khalid Nabilsi cited reduced CMO contribution as a key issue, noting that one major customer is shifting some manufacturing to domestic U.S. production—capacity Hikma said it cannot fully offer until the Bedford facility is ramped and commercialized in 2028. Nabilsi also pointed to delayed product launches and lower optimism around a small biosimilar component, including liraglutide.He descr ...

Hikma Pharma tumbles on softer guidance as buyback fails to soften pill Proactive uses images sourced from Shutterstock Hikma Pharmaceuticals PLC shares fell almost 16% to 1,390p after the drugs group delivered results for 2025 in line with forecasts but disappointed with weaker than expected guidance for 2026. Executive chair Said Darwazah will become full-time chief executive for the next two years, with current chief financial officer Khalid Nabilsi becoming deputy chief executive with responsibility f ...

Market Analysis by covering: JPMorgan Chase & Co, Eli Lilly and Company, Oracle Corporation, Broadcom Inc. Read 's Market Analysis on Investing.com ...

Core Insights - Idorsia Ltd reported strong financial and operational results for the full year 2025, setting a foundation for future growth and a catalyst-rich 2026 [1][2] Financial Performance - Net sales for 2025 reached CHF 221 million, a significant increase from CHF 113 million in 2024, driven by product sales of CHF 134 million and contract revenues of CHF 79 million [9] - Operating expenses decreased to CHF 268 million in 2025 from CHF 351 million in 2024, influenced by a one-off gain from a deal amendment [10] - The net loss for 2025 was CHF 112 million, an improvement from a net loss of CHF 264 million in 2024, resulting in a net loss per share of CHF 0.52 compared to CHF 1.45 in the previous year [11][12] Product Highlights - QUVIVIQ sales more than doubled, contributing significantly to the revenue growth and positioning the product for blockbuster status [2][6] - TRYVIO/JERAYGO has been approved in multiple regions and is showing promising results in hypertension treatment, with ongoing discussions for partnerships to maximize its global value [7][10] - The company is advancing its pipeline, including the upcoming pediatric insomnia study for daridorexant and the registration program for lucerastat in Fabry disease [6][8] Strategic Outlook - The guidance for 2026 anticipates continued growth in QUVIVIQ sales, projected to increase by approximately 50%, alongside investments in the lucerastat registration program and the immunology portfolio [8] - The company aims to transform the treatment paradigm in pediatric insomnia, with results expected in Q2 2026 [7] - Idorsia's operational restructuring initiated in Q4 2024 has contributed to improved financial performance and a strengthened balance sheet [11][13] Human Resources - The company reduced its workforce by over 200 positions in 2025, bringing the total number of permanent employees to 487 [20]